CMS Proposal to Cut 340B Drug Reimbursements Draws Mixed Reactions

The Centers for Medicare and Medicaid Services (CMS) recently unveiled a proposal to overhaul Medicare’s reimbursement rates for drugs purchased through the 340B program. This change, while aimed at reducing costs for both the government and patients, is likely to hit many large hospitals and safety-net providers hard, especially those serving a high proportion of low-income patients.

According to federal estimates highlighted in a KFF (Kaiser Family Foundation) analysis, the proposal would reduce drug payments by $4.85 billion in 2027, while saving Medicare beneficiaries $1.15 billion on cost-sharing for discounted drugs. However, these savings come at a significant cost to hospitals, which rely on 340B discounts to fund critical services and support vulnerable populations.

The proposed rule, released earlier this month, includes plans to cut 340B reimbursements from the current average sales price (ASP) plus 6% down to 33.4% below ASP. This dramatic reduction is intended to address concerns about the program’s financial sustainability and ensure that taxpayer dollars are used efficiently. However, it has sparked widespread criticism from hospital industry groups.

Impact on Hospitals

The CMS proposal is expected to have a disparate impact across different types of hospitals. Disproportionate Share Hospitals (DSH), which serve a higher percentage of low-income patients, are projected to see the most significant cuts. KFF estimates that DSH hospitals with a patient percentage of 0.35 or higher will experience a 5.8% net reduction in outpatient prospective payment system (OPPS) revenue due to the policy.

Urban hospitals with 500 beds or more are expected to face a 5.2% net reduction, while major teaching hospitals and government hospitals will see reductions of 4.3% and 3%, respectively. Nonprofit hospitals as a whole are projected to experience a modest 0.5% net reduction.

The cuts are particularly concerning for safety-net providers, which rely on the 340B program to fund essential services such as community health programs, charity care, and outreach initiatives. These hospitals often operate on thin margins and may struggle to maintain their operations without the financial support provided by 340B discounts.

What Comes Next

The CMS proposal has already triggered a strong backlash from hospital industry groups. Organizations like 340B Health have expressed deep concern over the potential impact on patient access to care, particularly for vulnerable populations. They argue that the proposed cuts could force hospitals to reduce or eliminate critical services, leading to worse health outcomes and higher long-term costs.

On the other hand, some policymakers and industry analysts view the proposal as a necessary step to address perceived inefficiencies in the 340B program. They argue that the current reimbursement rates are unsustainable and that reducing drug payments will help control overall healthcare costs.

The CMS is required by law to maintain budget neutrality, meaning that any cuts in one area must be offset by increases in another. To balance the proposed 340B cuts, the agency has proposed an 8.44% increase in reimbursement for non-drug outpatient services. However, this increase is unlikely to fully compensate for the loss of revenue from drug payments, especially for hospitals heavily reliant on the 340B program.

As the proposal moves forward, stakeholders will be closely monitoring the public comment period and any potential changes that may arise before the final rule is implemented. The outcome of this process could have lasting implications for hospital funding, patient access to care, and the overall sustainability of the healthcare system.